

Could Fucoxanthin Interaction with Lipid Rafts Mediate its Cytotoxicity in Cancer Cells?

Raimundo Gonçalves Oliveira-Junior, Valérie Thiéry, Odile Sergent, Martine Chevanne, Laurent Picot

► **To cite this version:**

Raimundo Gonçalves Oliveira-Junior, Valérie Thiéry, Odile Sergent, Martine Chevanne, Laurent Picot. Could Fucoxanthin Interaction with Lipid Rafts Mediate its Cytotoxicity in Cancer Cells?. *Journal of Oceanography and Marine Research*, 2016, 4 (1), pp.1000144. 10.4172/jomr.1000144 . hal-01391001

HAL Id: hal-01391001

<https://hal.archives-ouvertes.fr/hal-01391001>

Submitted on 2 Nov 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Could Fucoxanthin Interaction with Lipid Rafts Mediate its Cytotoxicity in Cancer Cells?

Oliveira-Junior RG^{1,2}, Thiéry V¹, Sergent O^{3,4}, Chevanne M^{3,4} and Picot L^{1*}

¹UMRi CNRS 7266 LIENSs University of La Rochelle, 17042 La Rochelle, France

²Center for Studies and Research on Medicinal Plants, Federal University of Sao Francisco Valley UNIVASF, Petrolina, Pernambuco State, Brazil

³UMR INSERM 1085 IRSET, UFR des Sciences Pharmaceutiques et Biologiques, 2, av Pr Léon Bernard, 35043 Rennes Cedex, France

⁴UMS 3080 BIOSIT, University of Rennes 1, 2, av Pr Léon Bernard, 35043 Rennes Cedex, France

*Corresponding author: Picot L, UMRi CNRS 7266 LIENSs University of La Rochelle, 17042 La Rochelle France, Tel: +33 (0)5 46 45 82 20; E-mail: laurent.picot@univ-lr.fr

Received date: April 21, 2016; Accepted date: July 18, 2016; Published date: July 29, 2016

Copyright: © 2016 Oliveira-Junior RG, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Fucoxanthin is a carotenoid present in brown micro- and macro algae, that induces apoptosis or autophagy in cancer cells grown *in vitro*. *In vivo* studies confirmed its interest as a natural anticancer compound, as it exerts antitumoral, antimetastatic and antiangiogenic activities in animal models. Studies focused on the pharmacology of fucoxanthin in cancer cells and tumors have revealed that it affects a wide panel of cellular, molecular and tissular processes, suggesting that its biological activity may be related in part to a nonspecific integration in cell membranes, and possible interaction with lipid rafts. Thus, preliminary data confirming this interaction of fucoxanthin with lipid rafts were obtained in mast cells and hepatoma WIF-B9 cells. We here discuss this hypothesis, in view of the critical function of lipid rafts in cancer cell survival, invasivity and communication with the tumoral microenvironment.

Keywords: Algae; Apoptosis; Cancer; Carotenoid; Fucoxanthin; Lipid raft; Phytoplankton; Pigment

Introduction

Plant and algae carotenoids have a great potential as natural anticancer compounds as they exert cytotoxic, antitumoral, antimetastatic, and antiangiogenic activities [1,2]. Particularly, fucoxanthin (Figure 1), a marine carotenoid purified from brown micro- and macroalgae, attracts extensive interest owing to its antiproliferative, pro-apoptotic and pro-autophagic activities, demonstrated in a large panel of cancer cells [3-14].




Figure 1: Chemical structure of fucoxanthin.

Its antitumoral activity was validated in animal models, in which it limits tumor growth, angiogenesis and invasivity, suggesting a possible use for clinical oncology [1,15]. Studies focused on the pharmacology of fucoxanthin in cancer cells and tumors have revealed that it induces cell cycle arrest in G0/G1 phases [5], cyclins and CDK down-regulation, CDK inhibitors up-regulation [16], as well as the common hallmarks of apoptosis (disturbance of the mitochondrial transmembrane potential, modulation of the expression of the Bcl-2 family proteins, activation of caspases/PARP/CAD, DNA fragmentation and phosphatidylserine exposure) (for review see [3]).

Fucoxanthin was also reported to inhibit mammalian topoisomerases [2,3], disturb the MAPK and NF- κ B pathways [17], enhance Gap junctional intercellular communication by up-regulating the expression of connexins [12], and reverse multi-drug resistance by interfering with drugs efflux systems [3,13]. It also inhibits matrix metalloproteases involved in tumor tissular invasivity [8,18], and induces autophagy in some cancer cell models [19]. This multimodal activity has led us to hypothesize that the cytotoxic activity of fucoxanthin may be related, at least in part, to a nonspecific integration into plasma and/or intracellular membranes, triggering a wide variety of cellular responses eventually leading to cancer cells apoptosis or autophagy. In support of this hypothesis, fucoxanthin contains two polar heads, separated by a polyene chain, that confer to the molecule a bolophile behaviour and the appropriate size for its integration into plasma and intracellular membranes. Accordingly, it is assumed that the first evolutionary function of carotenoids was to rigidify the cell membranes of archaeobacteria [20]. In algae, fucoxanthin locates in thylakoid membranes where it is tightly bound to chlorophyll molecules and apoproteins to form functional light-harvesting complexes [21]. In the same way, dietary carotenoids such as lutein and zeaxanthin concentrate in the rod outer segment membranes in human retina [22] where they play a key function in eye photoprotection against the deleterious wavelengths of blue light [23]. The first indication that carotenoids may interfere with lipid rafts in the plasma membrane has come from the observation that fucoxanthin, astaxanthin, zeaxanthin and β -carotene inhibit the antigen-induced degranulation of basophiles and mast cells [24]. In these models, it is assumed that fucoxanthin integration into lipid rafts blocks the translocation and aggregation of high affinity IgE receptors (Fc ϵ R1) and subsequently inhibits the signaling cascade triggering degranulation [24]. To address this hypothesis in other cell types, we recently investigated the interaction of fucoxanthin with subcellular

fractions obtained by ultracentrifugation of Wif-B9 hepatoma cells using the flotation method [25]. The WIF-B9 hepatic cell line, obtained by fusion of Fao rat hepatoma cells and WI 38 human fibroblasts, are highly differentiated and polarized cells, developing morphologic features close to primary rat and human hepatocytes. They constitute a relevant model for hepatotoxicity assays, xenobiotic metabolism studies and evaluation of xenobiotic interaction with lipid rafts [25]. In these preliminary investigations using cells treated with 10 μ M fucoxanthin for 24 h, we observed a tendency of fucoxanthin to preferentially incorporate into subcellular domains containing lipid rafts (66.5 %) when compared to those devoided of lipid rafts, according to absorbance increases at 446 nm per mg proteins (unpublished data). This observation is in line with the data obtained in mast cells, and suggests that fucoxanthin probably interacts with lipid rafts in several cell types. If confirmed, the demonstration of this interaction opens new perspectives to discuss the biological activity of fucoxanthin and understand why it exerts cytoprotective effects in normal cells, while it induces apoptosis or autophagy in cancer cells.

Fucoxanthin is usually considered as a potent antioxidant because of the presence of an allenic bond and hydroxyle function in its structure. In normal cells, in a context of low oxidative stress, it is conceivable that fucoxanthin integrates cell membranes in domains containing or not lipid rafts, and scavenges ROS that could trigger lipid oxidation and inflammation. Some studies suggest that the antioxidant activity of fucoxanthin may also be related to its ability to undergo ring-opening reactions on its 5,6 monoepoxide function and exert a pro-oxidant activity on surrounding molecules [26], eventually leading to an activation of the transcription factor Nrf2 (nuclear factor (erythroid-derived 2)- like2), stimulating the expression of antioxidant enzymes, such as glutathione peroxidase, and NAD(P)H quinone oxidoreductase 1 [26,27]. In cancer cells, because of an increased ROS production and high oxidative stress, integration of fucoxanthin in cell membranes may induce the generation of high levels of ROS, that exceed the capacity of antioxidant enzymes and eventually trigger apoptosis or autophagy. In support of this hypothesis, it was shown that fucoxanthin exerts a pro-apoptotic activity in human leukemia cells through a ROS-mediated BCL- xL pathway [28] and that this pro-apoptotic activity is inhibited by the antioxidant N-acetylcysteine. In addition to its pro- and antioxidant activity, it is reasonable to speculate that fucoxanthin interaction with lipid rafts may participate to its cytotoxicity in cancer cells. Lipid rafts are cholesterol and sphingolipid-enriched microdomains found in the plasma and Golgi membranes, characterized by their resistance to solubilization in nonionic detergents at low temperature and ability to float and concentrate in low-density fractions of a sucrose gradient after ultracentrifugation [29,30]. They are mobile and play a major function in protein trafficking and integration of signal transduction complexes, as they can rapidly include or exclude proteins and mediate protein-protein interactions. Lipid rafts are thus involved in key cellular functions, such as the control of cytoskeletal dynamics for cell adhesion and migration, or regulation of ion channels and signaling complexes trafficking to the plasma membrane. As such, they are also critically involved in adhesion, motility, invasivity, survival and proliferation of cancer cells, and represent an innovative target for the development of new anticancer drugs [31]. It has been shown that alteration of the lipid rafts composition (e.g. decrease in the cholesterol content) or integration of exogeneous lipids into lipid rafts (e.g. alkylphospholipid analogues such as edelfosine) could trigger cancer cells apoptosis [32-35]. It is also demonstrated that cell death can be initiated by activation of death domain receptors, located in lipid rafts

[33]. Previous studies have documented that some cancer cells contain an increased level of cholesterol-rich lipid rafts [36] and that a cholesterol-depleting agent such as methyl- β -cyclodextrin triggered Bcl-XL down regulation, caspase-3 activation and Akt inactivation [36]. These changes, that correspond to classical observations associated with apoptosis, have also been reported in cancer cells treated with fucoxanthin [3]. In this view, the selective cytotoxicity of fucoxanthin towards cancer cells may be explained in part by the elevated level of lipid rafts in cancer cells and increased ability of fucoxanthin to integrate their plasma membranes. Lipid rafts have been involved in the triggering of death receptor-mediated apoptosis through the recruitment and activation of Fas/CD95 death receptor [38]. Activation of Fas leads to the subsequent formation of the death-inducing signaling complex (DISC), that triggers apoptosis. Further studies should thus be undergone to determine if fucoxanthin cytotoxicity in cancer cells may be related to its ability to trigger Fas activation in lipid rafts and formation of the DISC. It is also well established that cancer cell migration and metastatic behaviour is controlled in part by ion channels associated in functional membrane complexes located in lipid rafts. As an example, the interaction between the SK3 potassium channel and Orai-1 calcium channel was documented as critical for the metastatic potential of breast cancer cells [38]. Accordingly, integration of apolar drugs such as ohmlin into lipid rafts has proved efficacy to disrupt the interaction of SK3 and Orai-1 channels in lipid rafts and inhibit the metastatic potential of cancer cells [38]. The demonstration that fucoxanthin can integrate lipid rafts opens the way for further studies to understand if its antimetastatic activity may be related to a disturbance in the interaction and functionality of such ion channels complexes located in lipid rafts. Additionally, dysregulation of ions channels expression is often observed in cancer cells [39]. These alterations promote cell proliferation, tissular invasivity and insensitivity to growth inhibitory signals. Fucoxanthin may counteract such dysregulations by disturbing ions channels integration and association in functional complexes in the plasma membrane. Ions channels and connexins also play a pivotal role to control the molecular dialogue between cancer cells and the tumor microenvironment. Fucoxanthin was reported to stimulate the expression of connexins 32 and 43 in cancer cells, enhance Gap junction intracellular communication and increase the concentration of intracellular Ca^{2+} [12]. Stimulation of the gap junctional communication facilitates the distribution of anticancer drugs within neighbouring tumor cells, and may explain in part why fucoxanthin is able to sensitize tumor cells to some anticancer drugs. Increase in the intracellular calcium concentration induced by fucoxanthin may also explain in part how fucoxanthin triggers cell cycle arrest, caspase activation and cytoskeleton reorganization. Changes in the whole cell shape and cell movement involve rapid and transient reorganization of membrane micro domains that are mostly mediated by the cytoskeleton dynamics in response to activation of membrane signaling pathways and local calcium concentration changes. Thus, integration of fucoxanthin in lipid rafts may induce major disturbances in these regulatory pathways and dysfunctions of the cytoskeleton. Fucoxanthin was also reported to decrease the expression of CD44 [8], a cell surface glycoprotein involved in cell-cell interactions, cell adhesion and migration, and interaction with matrix metalloproteases (MMPs), that plays a critical function in invasion of the tissular environment of the tumor by cancer cells. Lipid rafts play a crucial role in the localization and functionality of CD44 as proved using cholesterol-depleting agents, that stimulate CD44 shedding and suppress cancer cell migration [40]. Consequently, inhibition of MMPs by fucoxanthin and its physiological metabolite fucoxanthinol may be

related to their integration into lipid rafts and disturbance of CD44 expression. Fucoxanthin was also reported to inhibit angiogenesis in various tumor models or endothelial cells (e.g. HUVEC) by suppressing the mRNA expression of FGF-2 and its receptor FGFR-1, as well as their trans-activation factor, EGR-1 [40]. It also induces a decrease in the phosphorylation of FGF-2-mediated intracellular signaling proteins such as ERK1/2 and Akt, eventually leading to a repression of the migration of endothelial cells and inhibition of their differentiation into tube-like structures in Matrigel [40]. It is possible to hypothesize that incorporation of fucoxanthin may interfere with the function of growth factors receptors, that are located in lipid rafts. Finally, fucoxanthin may also disrupt protein palmitoylation or myristoylation, and alter their submembrane localization. The possible incorporation of fucoxanthin into organelle membranes, particularly mitochondrial membranes, and interaction with proteins of the Bcl-2 family, may also not be excluded. To conclude, the rigorous demonstration that fucoxanthin interacts with lipid rafts may provide a new clue to

understand the cellular and molecular mechanisms involved in its cytotoxicity in cancer cells. Continued exploration of fucoxanthin cytotoxicity in cancer cells should confirm if its interaction with lipid rafts is a key event triggering apoptosis or autophagy (Table 1).

Acknowledgements

This research was financially supported by the French cancer league (Comité 17 de la Ligue Nationale contre le Cancer). We also thank the "Cancéropôle Grand Ouest, axe Valorisation des produits de la mer en cancérologie and the Brazilian Society of Pharmacognosy for scientific support.

Conflicts of Interest

The authors declare no conflict of interest.

Topic	Reference numbers
Structure and biological activity of fucoxanthin and carotenoids in cancer cells	[1-18]
Biological functions of carotenoids in cell membranes	[19-22]
Interaction of carotenoids with lipid rafts	[23]
Cell model to study the integration of xenobiotics into lipid rafts	[24]
Antioxidant and pro-oxidant activity of fucoxanthin in animal cells and tissues	[25-27]
Structure and function of lipid rafts in cell membranes	[28,29]
Targeting lipid rafts in cancer cells	[30-36]
Ion channels, lipid rafts and cancer cells	[37,38]
Lipid rafts, cytoskeleton, cancer cells invasivity and tumor angiogenesis	[30,40]

Table 1: References cited in the text.

References

- Gagez AL, Thiery V, Pasquet V, Cadoret JP, Picot L (2012) Epoxy-carotenoids and Cancer. *Review. Curr Bioact Compd* 8: 109-141.
- Bolhassani A, Khavari A, Bathaie SZ (2014) Saffron and natural carotenoids: Biochemical activities and anti-tumor effects. *Biochim Biophys Acta* 1845: 20-30.
- Kumar SR, Hosokawa M, Miyashita K (2013) Fucoxanthin: a marine carotenoid exerting anti-cancer effects by affecting multiple mechanisms. *Mar Drugs* 11: 5130-5147.
- Yamamoto K, Ishikawa C, Katano H, Yasumoto T, Mori N (2011) Fucoxanthin and its deacetylated product, fucoxanthinol, induce apoptosis of primary effusion lymphomas. *Cancer Lett* 300: 225-234.
- Das SK, Hashimoto T, Shimizu K, Yoshida T, Sakai T, et al. (2005) Fucoxanthin induces cell cycle arrest at G0/G1 phase in human colon carcinoma cells through up-regulation of p21WAF1/Cip1. *Biochim Biophys Acta* 1726: 328-935.
- Nishino H, Tsushima M, Matsuno T, Tanaka Y, Okuzumi J, et al. (1992) Anti-neoplastic effect of halocynthiaxanthin, a metabolite of fucoxanthin. *Anticancer Drugs* 3: 493-497.
- Yu RX, Hu XM, Xu SQ, Jiang ZJ, Yang W (2011) Effects of fucoxanthin on proliferation and apoptosis in human gastric adenocarcinoma MGC-803 cells via JAK/STAT signal pathway. *Eur J Pharmacol* 657: 10-19.
- Chung TW, Choi HJ, Lee JY, Jeong HS, Kim CH, et al. (2013) Marine algal fucoxanthin inhibits the metastatic potential of cancer cells. *Biochem Biophys Res Commun* 439: 580-585.
- Sugawara T, Matsubara K, Akagi R, Mori M, Hirata T (2006) Antiangiogenic activity of brown algae fucoxanthin and its deacetylated product, fucoxanthinol. *J Agric Food Chem* 54: 9805-9810.
- Kim KN, Heo SJ, Kang SM, Ahn G, Jeon YJ (2010) Fucoxanthin induces apoptosis in human leukemia HL-60 cells through a ROS-mediated Bcl-xL pathway. *Toxicol In Vitro* 24: 1648-1654.
- Yoshiko S, Hoyoku N (2007) Fucoxanthin, a natural carotenoid, induces G1 arrest and GADD45 gene expression in human cancer cells. *In Vivo* 21: 305-309.
- Liu CL, Huang YS, Hosokawa M, Miyashita K, Hu ML (2009) Inhibition of proliferation of a hepatoma cell line by fucoxanthin in relation to cell cycle arrest and enhanced gap junctional intercellular communication. *Chem Biol Interact* 182: 165-172.
- Eid SY, El-Readi MZ, Wink M (2012) Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. *Phytomedicine* 19: 977-987.
- Martin LJ (2015) Fucoxanthin and Its Metabolite Fucoxanthinol in Cancer Prevention and Treatment. *Mar Drugs* 13: 4784-4798.
- Kim KN, Ahn G, Heo SJ, Kang SM, Kang MC, et al. (2013) Inhibition of tumor growth in vitro and in vivo by fucoxanthin against melanoma B16F10 cells. *Environ Toxicol Pharmacol* 35: 39-46.
- Das SK, Hashimoto T, Kanazawa K (2008) Growth inhibition of human hepatic carcinoma HepG2 cells by fucoxanthin is associated with down-regulation of cyclin D. *Biochim Biophys Acta* 1780: 743-749.

17. Kim KN, Heo SJ, Yoon WJ, Kang SM, Ahn G, et al. (2010) Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF- κ B and MAPKs in lipopolysaccharide- induced RAW 264.7 macrophages. *Eur J Pharmacol* 649: 369-375.
18. Nguyen VT, Qian ZJ, Lee B, Heo SJ, Kim KN, et al. (2014) Fucoxanthin derivatives from *Sargassum siliquastrum* inhibit matrix metalloproteinases by suppressing NF- κ B and MAPKs in human fibrosarcoma cells. *ALGAE* 29: 355-366.
19. Hou L, Gao C, Chen L, Hu G, Xie S (2013) Essential role of autophagy in fucoxanthin-induced cytotoxicity to human epithelial cervical cancer HeLa cells. *Acta Pharmacol Sin* 34: 1403-1410.
20. Vershinin A (1999) Biological functions of carotenoids--diversity and evolution. *Biofactors* 10: 99-104.
21. Takaichi S (2011) Carotenoids in algae: distributions, biosyntheses and functions. *Mar Drugs* 9: 1101-1118.
22. Krinsky NI, Landrum JT, Bone RA (2003) Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. *Annu Rev Nutr* 23: 171-201.
23. Stahl W, Sies H (2005) Bioactivity and protective effects of natural carotenoids. *Biochim Biophys Acta* 1740: 101-107.
24. Sakai S, Sugawara T, Matsubara K, Hirata T (2009) Inhibitory effect of carotenoids on the degranulation of mast cells via suppression of antigen-induced aggregation of high affinity IgE receptors. *J Biol Chem* 284: 28172-28179.
25. Nourissat P, Travert M, Chevanne M, Tekpli X, Rebillard A, et al. (2008) Ethanol induces oxidative stress in primary rat hepatocytes through the early involvement of lipid raft clustering. *Hepatology* 47: 59-70.
26. Liu CL, Chiu YT, Hu ML (2011) Fucoxanthin enhances HO-1 and NQO1 expression in murine hepatic BNL CL.2 cells through activation of the Nrf2/ARE system partially by its pro-oxidant activity. *J Agric Food Chem* 59: 11344-11351.
27. Ha AW, Na SJ, Kim WK (2013) Antioxidant effects of fucoxanthin rich powder in rats fed with high fat diet. *Nutr Res Pract* 7: 475-480.
28. Brown DA, London E (1998) Functions of lipid rafts in biological membranes. *Annu Rev Cell Dev Biol* 14: 111-36.
29. Simons K, Ikonen E (1997) Functional rafts in cell membranes. *Nature* 387: 569-572.
30. Mollinedo F, Gajate C (2014) Lipid rafts as major platforms for signaling regulation in cancer. *Adv Biol Regul* 57: 130-146.
31. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR (2005) Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. *J Clin Invest* 115: 959-968.
32. Gajate C, Del Canto-Jañez E, Acuña AU, Amat-Guerri F, Geijo E, et al. (2004) Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. *J Exp Med* 200: 353-365.
33. Gajate C, Mollinedo F (2007) Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. *Blood* 109: 711-719.
34. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M (2003) Anti-cancer alkyl- lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. *Anticancer Drugs* 14: 167-173.
35. Li YC, Park MJ, Ye SK, Kim CW, Kim YN (2006) Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. *Am J Pathol* 168: 1107-1118; quiz 1404-1405.
36. Gajate C, Gonzalez-Camacho F, Mollinedo F (2009) Involvement of Raft Aggregates Enriched in Fas/CD95 Death-Inducing Signaling Complex in the Antileukemic Action of Edelfosine in Jurkat Cells. *PLoS One* 4: e5044.
37. Chantome A, Potier-Cartereau M, Clarysse L, Fromont G, Marionneau-Lambot S, et al. (2013) Pivotal Role of the Lipid Raft SK3-Orai1 Complex in Human Cancer Cell Migration and Bone Metastases. *Cancer Res* 73: 4852-4861.
38. Pedersen SF, Stock C (2013) Ion Channels and Transporters in Cancer: Pathophysiology, Regulation, and Clinical Potential. *Cancer Res* 73: 1658-1661.
39. Oliferenko S (1999) Analysis of CD44-containing Lipid Rafts: Recruitment of Annexin II and Stabilization by the Actin Cytoskeleton. *J Cell Biol* 146: 843-854.
40. Ganesan P, Matsubara K, Sugawara T, Hirata T (2013) Marine algal carotenoids inhibit angiogenesis by down-regulating FGF-2-mediated intracellular signals in vascular endothelial cells. *Mol Cell Biochem* 380: 1-9.